Literature DB >> 22473520

Receiver operating characteristic analysis of sphincter electromyography for parkinsonian syndrome.

Tatsuya Yamamoto1, Ryuji Sakakibara, Tomoyuki Uchiyama, Chiharu Yamaguchi, Fumio Nomura, Takashi Ito, Mitsuru Yanagisawa, Masashi Yano, Yusuke Awa, Tomonori Yamanishi, Takamichi Hattori, Satoshi Kuwabara.   

Abstract

AIMS: We performed receiver operating characteristic (ROC) analysis to determine the ability of sphincter electromyography (EMG) to distinguish multiple system atrophy (MSA) from other parkinsonisms. The following was determined: (1) the appropriate motor unit potential (MUP) parameter among duration, phase, and amplitude; (2) the desirable parameter of our duration criteria; that is, more than 20% MUPs having >10 ms duration (criteria a) or mean duration >10 ms (criteria b).
METHODS: We retrospectively reviewed 441 case records where sphincter EMG were performed in patients with parkinsonian syndromes: MSA, n = 263; Parkinson's disease, n = 129; dementia with Lewy bodies, n = 25; and progressive supranuclear palsy, n = 24. We performed ROC analysis of the data sets.
RESULTS: The area under the curve used to differentiate MSA from other parkinsonian syndromes was 0.68 in duration, 0.57 in phase, and 0.51 in amplitude, respectively; these values were statistically significant. With regard to our duration criteria, area under the curve was 0.69 for the average duration of MUPs (criteria b) and 0.67 for percentage of MUPs of duration >10 ms (criteria a); these values were also statistically significant.
CONCLUSIONS: This study suggests that duration is appropriate parameter for the differentiation of MSA. However, the area under the curve of the mean duration was insufficient to confirm the diagnosis; sphincter EMG should be used as a supportive diagnostic tool for the diagnosis of MSA.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22473520     DOI: 10.1002/nau.22208

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN: 0733-2467            Impact factor:   2.696


  7 in total

Review 1.  Urological dysfunction in synucleinopathies: epidemiology, pathophysiology and management.

Authors:  Ryuji Sakakibara; Fuyuki Tateno; Tatsuya Yamamoto; Tomoyuki Uchiyama; Tomonori Yamanishi
Journal:  Clin Auton Res       Date:  2017-11-09       Impact factor: 4.435

2.  Underactive and overactive bladders are related to motor function and quality of life in Parkinson's disease.

Authors:  Zhi Liu; Tomoyuki Uchiyama; Ryuji Sakakibara; Tatsuya Yamamoto
Journal:  Int Urol Nephrol       Date:  2015-03-20       Impact factor: 2.370

Review 3.  Gastrointestinal dysfunction in movement disorders.

Authors:  Ryuji Sakakibara
Journal:  Neurol Sci       Date:  2021-02-04       Impact factor: 3.307

Review 4.  Lower urinary tract dysfunction in Parkinsonian syndromes.

Authors:  Ekawat Vichayanrat; Claire Hentzen; Amit Batla; Sara Simeoni; Valeria Iodice; Jalesh N Panicker
Journal:  Neurol Sci       Date:  2021-07-28       Impact factor: 3.307

5.  The Utility of Post-Void Residual Volume versus Sphincter Electromyography to Distinguish between Multiple System Atrophy and Parkinson's Disease.

Authors:  Tatsuya Yamamoto; Masato Asahina; Yoshitaka Yamanaka; Tomoyuki Uchiyama; Shigeki Hirano; Miki Fuse; Yasuko Koga; Ryuji Sakakibara; Satoshi Kuwabara
Journal:  PLoS One       Date:  2017-01-06       Impact factor: 3.240

6.  Differential Diagnosis Of Multiple-System Atrophy With Parkinson's Disease By External Anal- And Urethral-Sphincter Electromyography.

Authors:  Feng Qiu; Kunyu Wang; Tingting Li; Dandan Song; Zhiwei Wang; Hailing Zhang; Jianguo Liu; Ming Ren; Xiaokun Qi
Journal:  Neuropsychiatr Dis Treat       Date:  2019-11-05       Impact factor: 2.570

7.  Urinary Dysfunctions Are More Severe in the Parkinsonian Phenotype of Multiple System Atrophy.

Authors:  Tatsuya Yamamoto; Masato Asahina; Yoshitaka Yamanaka; Tomoyuki Uchiyama; Shigeki Hirano; Atsuhiko Sugiyama; Ryuji Sakakibara; Satoshi Kuwabara
Journal:  Mov Disord Clin Pract       Date:  2016-01-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.